Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Collaboration › Details

AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004

 

Period Period 2023-11-09
Region Region ALL
Organisations Partner, 1st AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Partner, 2nd Eccogene (CN)
Products Product ECC5005 (Eccogene / AstraZeneca)
  Product 2 obesity drug
Document Source AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]".
     

   
Record changed: 2024-02-05

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top